CBDBY yields 301.09% · PFE yields 6.13%● Live data
📍 CBDBY pulled ahead of the other in Year 1
Combined, CBDBY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CBDBY + PFE for your $10,000?
Companhia Brasileira de Distribuição engages in the retail of food, clothing, home appliances, electronics, and other products through its chain of supermarkets, specialized stores, and department stores in Brazil. It operates in Brazilian Retail, Grupo Éxito, and Other Businesses segments. The company sells non-perishables, beverages, fruits, vegetables, meat, breads, cold cuts, dairy products, cleaning products, disposable products, and personal care products; and home appliances and other non-food products, such as clothing and baby items, shoes and accessories, household articles, books, magazines, CDs and DVDs, stationery, toys, sports and camping gears, furniture, mobile phones, mattresses, pet products, and gardening equipment and tools, as well as electronic products, including personal computers, software, computer accessories, and sound and image systems. It also offers medications and cosmetics at its drugstores; and non-food products at gas stations, as well as rents commercial spaces and e-commerce sales. The company operates its supermarkets under the banners of Pão de Açúcar, Extra Supermercado, Mercado Extra, and Compre Bem; hypermarkets under the banner of Extra Hiper; and proximity stores under the banners of Mini Extra, Minuto Pão de Açúcar, Pão de Açúcar Adega, and Aliados Minimercado; and gas stations and drugstores under the banners of Extra and Pão de Açúcar, as well as sells its products through its Websites. As of December 31, 2021, it operated 667 stores, 74 gas stations, and 68 drugstores in 16 Brazilian states and the Federal District, as well as 15 distribution centers and warehouses across Brazil. The company was founded in 1948 and is headquartered in São Paulo, Brazil.
Full CBDBY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.